Navigation Links
Late-breaking results of clinical trial on therapeutic endovascular cooling reported at TCT 2008
Date:10/14/2008

WASHINGTON, DC OCTOBER 14, 2008 Late-breaking results from the COOL RCN (COOLing to Prevent Radio Contrast Nephropathy in Patients Undergoing Diagnostic or Interventional Catheterization) Trial were presented during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

The prospective, randomized, multicenter clinical study was designed to evaluate the safety and effectiveness of catheter-based endovascular cooling for preventing acute kidney failure in high risk patients often a serious side effect of radiographic contrast agents which are administered to all patients undergoing diagnostic or interventional catheterization procedures. Acute kidney failure following exposure to intravascular contrast agents is known as radiocontrast nephropathy (RCN).

Principal Investigator Gregg W. Stone, M.D., CRF Chairman, Professor of Medicine and the Director of Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center, presented the findings of the study.

Patients with pre-existing renal insufficiency, heart disease, or diabetes are at particularly high risk of developing RCN after cardiac catheterization. Mild hypothermia to protect the kidneys of high risk patients while they are undergoing cardiac catheterization is one potential therapy.

According to Dr. Stone, "This is a novel approach to preventing a common but serious side effect of radiographic contrast agents. The body is cooled from the inside out by approximately 7 degrees Fahrenheit."

The COOL RCN system enables the rapid induction of hypothermia in a conscious or unconscious patient by use of a venous heat exchange catheter. It provides very rapid, precise cooling, maintenance, and re-warming of the patient's core body temperature. A catheter is threaded into the femoral vein and positioned in the inferior vena cava. As cool sterile saline is circulated within the catheter, blood flowing past the catheter is cooled and, in turn, reduces body temperature. To re-warm the patient, the sterile saline within the catheter is simply warmed.

In the COOL RCN trial, 136 patients were recruited between March 2006 and August 2007, and researchers were able to evaluate 128 patients. In the pilot study, 32 patients (median age 71, 50% diabetes) were hydrated and cooled to 33-34○C less than 90 minutes prior to and for 3 hours after contrast was administered. Cooling had to be achieved before the first administration of contrast agent. The target core temperature in patients was 33○C; no contrast was administered before 34○C.

The observed rate of RCN in the control arm - 18.6% - was lower than had been anticipated - 35%. This fact, coupled with the enrollment of only 136 of 400 planned patients (34%) resulted in a wide point estimate for the treatment effect of systemic hypothermia.

Dr. Stone noted the trial was abbreviated due to a lack of funding. However, he concluded that based on the limited number of participants, "in patients at high risk for RCN undergoing invasive cardiology procedures, cooling may be safely achieved and is well-tolerated, but these results do not point to a significant reduction in RCN."


'/>"/>

Contact: Judy Romero
jromero@crf.org
646-957-6898
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Eric J. Topol, M.D., to Present Late-Breaking Lecture About Advancements in Genomics of Cardiovascular Disease at ACCs 57th Annual Scientific Session
2. Johnson & Johnson Reports 2008 Third-Quarter Results:
3. National Psoriasis Foundation Releases 2008 Study Results
4. Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008
5. Accuray Incorporated to Report First Quarter Fiscal Year 2009 Financial Results
6. Quest Diagnostics to Release Third Quarter 2008 Financial Results
7. Disaboom Announces Preliminary Third Quarter Results
8. Test Results from Pharmacy Healthcare Solutions Show not all Prescription Packaging is Created Equal
9. Latest LOGICARE(R) EDIS User Sees Tremendous Results
10. Dynatronics Announces Fiscal Year 2008 Operating Results
11. Dynatronics to Release Fourth Quarter and Year-end Results Monday, September 29, 2008; Conference Call Set for 3:00 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an ... an educational webinar, they will present the line of epMotion automated liquid handling ... easy you can automate everyday pipetting tasks. , Ideal for scientists and lab ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based ... area, is spearheading a regional charity campaign organized to provide support to Christina Upchurch ... of this year, Christina and her children returned from out of town to find ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the ... efforts with its product now available through Jet.com. , After 25 years of ... powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017 AccuGenomics, Inc., a diagnostic company ... announced that the company has provided an AccuKit to ... Carolina at Chapel Hill and to Qura Therapeutics for ... and quantify HIV reservoir and viral expression in human ... HIV Cure Center is a joint initiative between the ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: